Treatment of childhood leukemia has improved markedly in recent decades, with long-term cure achieved in most patients who have access to modern, highly intensive treatment regimens. However, some patients develop resistance to the steroid drugs which are a key part of combination chemotherapy treatments, which results in poor clinical outcomes. In the third week of PLOS Medicine's ongoing special issue on cancer genomics, principal investigator Jules Meijerink of the Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands and colleagues seek to identify mechanisms underlying treatment resistance in children with T-cell acute lymphoblastic leukemia (T-ALL) by combining genomic DNA sequencing and chromosomal copy-number analyses, and suggest a new approach to therapy.
‘Inhibition of MEK-ERK or PI3K/AKT/mTOR signaling could enhance steroid sensitivity in children with T-cell acute lymphoblastic leukemia (T-ALL) and potentially improve patient outcomes.’
Tweet it Now
As described in their Research Article, Meijerink and
colleagues studied genetic changes in leukemic cells from pediatric
T-ALL patients before treatment. The researchers found specific gene
mutations affecting signaling inside cells, involving the interleukin 7
receptor and downstream molecules, that were associated with steroid
resistance and adverse clinical outcome. Drugs designed to target
individual signaling proteins were able to restore steroid sensitivity
to primary leukemic cells from patients.Discussing the research in an accompanying Perspective article, Steven Goossens and Pieter Van Vlierberghe conclude that "inhibition of MEK-ERK or PI3K/AKT/mTOR signaling could enhance steroid sensitivity in T-ALL and potentially improve patient outcomes, a notion that warrants investigation in future prospective clinical trials."
Source-Eurekalert